Table 3.

Prespecified study endpoints

	Events (n)		Hazard ratio (95% CI)	p*
	Placebo	Clodronate
Disease-free survival	312	286	0.91 (0.78 – 1.07)	0.27
Overall survival	167	140	0.84 (0.67 – 1.05)	0.13
Recurrence-free interval	177	148	0.83 (0.67 – 1.04)	0.10
Bone metastasis-free interval	80	61	0.77 (0.55 – 1.07)	0.12
Non-bone metastasis-free survival	105	78	0.74 (0.55 – 1.00)	0.047

^*By log-rank test